Loading data for DFTX — first visit, this takes a few seconds.
Definium Therapeutics Inc... (DFTX)
NasdaqGS: DFTX
· Real-Time Price · USD
45.82
-0.36 (-0.78%)
At close: Aug 20, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Definium Therapeutics Inc. (DFTX) Stock Price, Analysis & Data
-0.78% (1D)
No data available
| Bid | 33.63 |
| Market Cap | 6.1B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -353.78M |
| 2.26 | |
| -3.43 | |
| n/a | |
| -24.21 | |
| P/B (ttm) | 6.64 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 57.7 |
| Volume | 1,746,550 |
| Avg. Volume (20D) | 3,028,916 |
| Open | 47.00 |
| Previous Close | 46.18 |
| Day's Range | 44.59 - 47.29 |
| 52-Week Range | 8.70 - 49.70 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum d...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 15, 2016
Employees 105
Stock Exchange NasdaqGS
Ticker Symbol DFTX
Website https://definiumtx.com
Financial Performance
In 2025, Definium Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -183.79M, an increase of 69.12%.
Financial StatementsEarnings Surprise
Definium Therapeutics has released their quarterly earnings on Aug 6, 2026:
Page 1 of 2